Consistent with these findings, patients with congenital secondary IGF1 deficiency are less likely to develop cancer (Steuerman et al., 2011), while mice with reduced circulating Igf1 levels experience delayed onset of mammary tumours compared to controls (Wu et al., 2003). This evidence concerns the gene IGF1 and breast cancer.